Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 6, 2014, Pages 787-793

  Olson, Amanda L ^a   Dahi, Parastoo B ^a,b   Zheng, Junting ^a   Devlin, Sean M ^a   Lubin, Marissa ^a   Gonzales, Anne Marie ^a   Giralt, Sergio A ^a,b   Perales, Miguel Angel ^a,b   Papadopoulos, Esperanza B ^a,b   Ponce, Doris M ^a,b   Young, James W ^a,b   Kernan, Nancy A ^a   Scaradavou, Andromachi ^a   O'Reilly, Richard J ^a   Small, Trudy N ^a   Papanicolaou, Genovefa ^a,b   Barker, Juliet N ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cord blood transplantation; Cytomegalovirus; HHV 6 encephalitis; Human herpesvirus 6

Indexed keywords

ACICLOVIR; CALCINEURIN INHIBITOR; FOSCARNET; GRANULOCYTE COLONY STIMULATING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; LYMPHOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHILD; CORD BLOOD STEM CELL TRANSPLANTATION; CORRELATION ANALYSIS; CYTOMEGALOVIRUS; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX ENCEPHALITIS; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 6; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PROGNOSIS; RECIPIENT; RISK FACTOR; SCHOOL CHILD; VIREMIA; VIRUS LOAD; VIRUS REACTIVATION; ADVERSE EFFECTS; ENCEPHALITIS, VIRAL; FEMALE; INFANT; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PRESCHOOL CHILD; ROSEOLOVIRUS INFECTIONS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTILYMPHOCYTE SERUM; CHILD; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; ENCEPHALITIS, VIRAL; FEMALE; HERPESVIRUS 6, HUMAN; HUMANS; INCIDENCE; INFANT; MALE; MIDDLE AGED; RISK FACTORS; ROSEOLOVIRUS INFECTIONS; VIREMIA; YOUNG ADULT;

EID: 84899953841     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.02.010     Document Type: Article

References (53)

1. Ogata M. Human herpesvirus 6 in hematological malignancies. J Clin Exp Hematop 2009, 49:57-67.
2. De Bolle L., Naesens L., De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev 2005, 18:217-245.
3. Gompels U.A., Macaulay H.A. Characterization of human telomeric repeat sequences from human herpesvirus 6 and relationship to replication. J Gen Virol 1995, 76(Pt 2):451-458.
4. de Pagter P.J., Schuurman R., Meijer E., et al. Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation. J Clin Virol 2008, 43:361-366.
5. Kadakia M.P., Rybka W.B., Stewart J.A., et al. Human herpesvirus 6: infection and disease following autologous and allogeneic bone marrow transplantation. Blood 1996, 87:5341-5354.
6. Yoshikawa T., Suzuki K., Ihira M., et al. Prediction of human herpesvirus 6 infection after allogeneic bone marrow transplantation. Blood 1998, 92:2597-2599.
7. Drobyski W.R., Knox K.K., Majewski D., Carrigan D.R. Brief report: fatal encephalitis due to variant B human herpesvirus-6 infection in a bone marrow-transplant recipient. N Engl J Med 1994, 330:1356-1360.
8. Zerr D.M., Corey L., Kim H.W., et al. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis 2005, 40:932-940.
9. Yoshikawa T. Human herpesvirus 6 causes hepatitis in transplant recipients. Intern Med 2006, 45:417-418.
10. Buchbinder S., Elmaagacli A.H., Schaefer U.W., Roggendorf M. Human herpesvirus 6 is an important pathogen in infectious lung disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000, 26:639-644.
11. Yamane A., Mori T., Suzuki S., et al. Risk factors for developing human herpesvirus 6 (HHV-6) reactivation after allogeneic hematopoietic stem cell transplantation and its association with central nervous system disorders. Biol Blood Marrow Transplant 2007, 13:100-106.
12. Singh N., Paterson D.L. Encephalitis caused by human herpesvirus-6 in transplant recipients: relevance of a novel neurotropic virus. Transplantation 2000, 69:2474-2479.
13. Hill J.A., Koo S., Guzman Suarez B.B., et al. Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis. Biol Blood Marrow Transplant 2012, 18:1638-1648.
14. Vu T., Carrum G., Hutton G., et al. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2007, 39:705-709.
15. Scheurer M.E., Pritchett J.C., Amirian E.S., et al. HHV-6 encephalitis in umbilical cord blood transplantation: a systematic review and meta-analysis. Bone Marrow Transplant 2013, 48:574-580.
16. Zerr D.M., Fann J.R., Breiger D., et al. HHV-6 reactivation and its effect on delirium and cognitive functioning in hematopoietic cell transplantation recipients. Blood 2011, 117:5243-5249.
17. Burd E.M., Knox K.K., Carrigan D.R. Human herpesvirus-6-associated suppression of growth factor-induced macrophage maturation in human bone marrow cultures. Blood 1993, 81:1645-1650.
18. Ljungman P., Wang F.Z., Clark D.A., et al. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. Br J Haematol 2000, 111:774-781.
19. Radonic A., Oswald O., Thulke S., et al. Infections with human herpesvirus 6 variant B delay platelet engraftment after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005, 131:480-482.
20. Yoshikawa T. Significance of human herpesviruses to transplant recipients. Curr Opin Infect Dis 2003, 16:601-606.
21. de Pagter P.J., Schuurman R., Keukens L., et al. Human herpes virus 6 reactivation: important predictor for poor outcome after myeloablative, but not non-myeloablative allo-SCT. Bone Marrow Transplant 2013, 48:1460-1464.
22. Ogata M., Kikuchi H., Satou T., et al. Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. J Infect Dis 2006, 193:68-79.
23. Wang L.R., Dong L.J., Zhang M.J., Lu D.P. The impact of human herpesvirus 6B reactivation on early complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:1031-1037.
24. Savolainen H., Lautenschlager I., Piiparinen H., et al. Human herpesvirus-6 and -7 in pediatric stem cell transplantation. Pediatr Blood Cancer 2005, 45:820-825.
25. Hentrich M., Oruzio D., Jager G., et al. Impact of human herpesvirus-6 after haematopoietic stem cell transplantation. Br J Haematol 2005, 128:66-72.
26. Maeda Y., Teshima T., Yamada M., et al. Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation. Br J Haematol 1999, 105:295-302.
27. Chevallier P., Hebia-Fellah I., Planche L., et al. Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source. Bone Marrow Transplant 2010, 45:1204-1211.
28. Shimazu Y., Kondo T., Ishikawa T., et al. Human herpesvirus-6 encephalitis during hematopoietic stem cell transplantation leads to poor prognosis. Transplant Infect Dis 2013, 15:195-201.
29. Dulery R., Salleron J., Dewilde A., et al. Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study. Biol Blood Marrow Transplant 2012, 18:1080-1089.
30. de Pagter P.J., Schuurman R., Visscher H., et al. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome. Biol Blood Marrow Transplant 2008, 14:831-839.
31. Barker J.N., Byam C., Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood 2011, 117:2332-2339.
32. Ponce D.M., Zheng J., Gonzales A.M., et al. Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:1316-1326.
33. Sauter C., Abboud M., Jia X., et al. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. Biol Blood Marrow Transplant 2011, 17:1460-1471.
34. Reddy S., Manna P. Quantitative detection and differentiation of human herpesvirus 6 subtypes in bone marrow transplant patients by using a single real-time polymerase chain reaction assay. Biol Blood Marrow Transplant 2005, 11:530-541.
35. Zerr D.M. Human herpesvirus 6 and central nervous system disease in hematopoietic cell transplantation. J Clin Virol 2006, 37(Suppl. 1):S52-S56.
36. Mariotte E., Schnell D., Scieux C., et al. Significance of herpesvirus 6 in BAL fluid of hematology patients with acute respiratory failure. Infection 2011, 39:225-230.
37. Ogata M., Satou T., Kawano R., et al. Plasma HHV-6 viral load-guided preemptive therapy against HHV-6 encephalopathy after allogeneic stem cell transplantation: a prospective evaluation. Bone Marrow Transplant 2008, 41:279-285.
38. Betts B.C., Young J.A., Ustun C., et al. Human herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary?. Biol Blood Marrow Transplant 2011, 17:1562-1568.
39. Eapen M., Rubinstein P., Zhang M.J., et al. Comparison of outcomes after transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukemia. Lancet 2007, 369:1947-1954.
40. Brunstein C.G., Gutman J.A., Weisdorf D.J., et al. Allogeneic hematopoietic cell transplantation for hematological malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010, 116:4693-4699.
41. Brunstein C.G., Eapen M., Ahn K.W., et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012, 119:5591-5598.
42. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351:2265-2275.
43. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004, 351:2276-2285.
44. Tunkel A.R., Glaser C.A., Bloch K.C., et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008, 47:303-327.
45. Zerr D.M., Boeckh M., Delaney C., et al. HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:1700-1708.
46. Clark D.A., Nacheva E.P., Leong H.N., et al. Transmission of integrated human herpesvirus 6 through stem cell transplantation: implications for laboratory diagnosis. J Infect Dis 2006, 193:912-916.
47. Preiksaitis J.K., Pang X.L., Fox J.D., et al. Interlaboratory comparison of Epstein-Barr virus viral load assays. Am J Transplant 2009, 9:269-279.
48. Pang X.L., Fox J.D., Fenton J.M., et al. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009, 9:258-268.
49. Gerdemann U., Keukens L., Keirnan J.M., et al. Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood 2013, 121:207-218.
50. Wagstaff A.J., Bryson H.M. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994, 48:199-226.
51. Ishiyama K., Katagiri T., Hoshino T., et al. Preemptive therapy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk patients after hematopoietic SCT. Bone Marrow Transplant 2011, 46:863-869.
52. Ishiyama K., Katagiri T., Ohata K., et al. Safety of pre-engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation. Transplant Infect Dis 2012, 14:33-39.
53. Milano F., Pergam S.A., Xie H., et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood 2011, 118:5689-5696.